



# Ami Organics Limited

CIN. : L24100GJ2007PLCO51093

Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

**August 12, 2024**

To,  
The Listing Department,  
**BSE LIMITED,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai- 400 001

To,  
The Listing Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C-1,  
G-Block, Bandra Kurla Complex,  
Mumbai -400051

**Scrip Code: 543349**

**NSE Symbol: AMIORG**

**Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release discussing the financial results of first quarter ended as on June 30, 2024.

This Press Release will be available on the website of the Company [www.amiorganics.com](http://www.amiorganics.com).

Kindly take the same on record.

Yours faithfully,

**For, AMI ORGANICS LIMITED**

Digitally signed by  
EKTA KUMARI  
SRIVASTAVA  
Date: 2024.08.12  
15:53:16 +05'30'

**Ekta Kumari Srivastava**  
**Company Secretary & Compliance Officer**



Encl: Press Release



[Info@amiorganics.com](mailto:Info@amiorganics.com)



[www.amiorganics.com](http://www.amiorganics.com)



+91 72279 77744 / 75730 15366



## Ami Organics Limited reports Q1FY25 Results

### Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore

Surat, August 12, 2024: **Ami Organics Limited** (AMI) (BSE: 543349, NSE: AMIORG), a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the first quarter ended June 30, 2024.

#### Consolidated Financial Results – Q1FY25:

Particulars (Rs. Mn)	Q1FY25	Q1FY24	YoY	Q4FY24	QoQ
<b>Revenue from Operations</b>	<b>1,767</b>	<b>1,537</b>	14.9%	<b>2,250</b>	-21.5%
<b>Gross Profit</b>	<b>743</b>	<b>736</b>	0.9%	<b>900</b>	-17.4%
<i>Gross Margin</i>	42.1%	47.9%		40.0%	
<b>EBITDA</b>	<b>295</b>	<b>340</b>	-13.2%	<b>432</b>	-31.6%
<i>EBITDA Margin</i>	16.7%	22.1%		19.2%	
<b>PAT</b>	<b>147</b>	<b>222</b>	-33.9%	<b>257</b>	-42.8%
<i>PAT Margin</i>	8.3%	14.5%		11.4%	

**Commenting on results, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited,** said: *“I am pleased to report that we continue to successfully navigate the challenging industry landscape, achieving strong revenue of ₹176 crore, which represents a 14.9% year-over-year growth. This growth was primarily driven by our core pharmaceutical business, while the specialty chemicals segment saw a modest 10% increase.*

*During the quarter, we also successfully completed the Good Manufacturing Practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan, with no critical or major observations. To our knowledge, we may be the only company in India to have successfully passed both USFDA and PMDA inspections in the advanced pharmaceutical intermediate sector.*

*Historically, Q1 is always lowest quarter in terms of revenue each financial year since inception, and we typically see sequential growth from Q1 to Q4. I anticipate similar strong sequential growth in the coming quarters. Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year.”*

**PRESS RELEASE**

For Immediate dissemination



**Key Results Highlights (Q1FY25 Consolidated):**

- ✓ **Revenue from operations** for Q1FY25 grew by **14.9% YoY** to **Rs. 1,767 mn**
- ✓ The **gross margin** for the quarter was at **42.1%**.
- ✓ **EBITDA** for the quarter came at **Rs. 295 mn** down 13.2% YoY compared to Rs. 340 mn in Q1FY24.
- ✓ **EBITDA margin** for the quarter was at **16.7%** as compared to 22.1% in Q1FY24. EBITDA margins contracted due to lower gross margins coupled with higher employee expenses led by annual increments as well as new hiring for Ankleshwar plant.
- ✓ **PAT** for the quarter was **Rs. 147 mn**. **PAT margin** for the quarter was **8.3%**. PAT margins were impacted due to higher finance cost as well as higher depreciation cost.

**Key Business highlights:**

- ✓ **Export at 63%; domestic business at 37%**
- ✓ **Successfully concluded** Good Manufacturing Practices (**GMP**) inspection by Pharmaceutical and Medical Devices Agency, Japan (“**PMDA**”) without any critical/major observation.
- ✓ Incorporated “**ENCHEM AMI ORGANICS PRIVATE LIMITED**”, as a wholly owned subsidiary company of Ami Organics Electrolytes Private Limited (a wholly owned subsidiary of Ami Organics Limited)
- ✓ **Funds Raised** – Successfully raised Rs. 500cr. through QIP and Preferential allotment to deleverage balance sheet and support capex.
- ✓ As of July 2024, a total **debt of Rs. 253cr has been repaid** and the company is now net debt zero company.

**PRESS RELEASE**

For Immediate dissemination



**AMI ORGANICS LTD.**

**ABOUT AMI ORGANICS LIMITED:**

Ami Organics, headquartered at Surat, is a research and development (“R&D”) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates (“Pharma Intermediates”) for regulated and generic active pharmaceutical ingredients (“APIs”) and chemicals for New Chemical Entities (“NCE”), and other specialty chemicals including parabens and paraben formulations, methyl salicylate, semiconductor chemicals, electrolyte additives and niche key starting materials (“KSM”) for cosmetics, fine chemicals and agrochemical industries.

The Pharma Intermediates, find application in certain high-growth therapeutic areas including anti-depressant, anti-cancer, anti-retroviral, anti-Parkinson, and seizure disorder. Ami Organics is the market leader for various key intermediates across the globe and the first company in India outside of China to spearhead the pioneering development of electrolyte additives on a global scale.

**CAUTIONARY STATEMENT:**

*This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Ami Organics has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

**For details, please contact:**

<p><b>Investor Relations at Ami Organics</b> Ekta Srivastava, Company Secretary &amp; Compliance Officer <a href="mailto:cs@amiorganics.com">cs@amiorganics.com</a></p> <p><b>Senior Manager – Investor Relations</b> Mr. Rahul Thakur <a href="mailto:Rahul.thakur@amiorganics.com">Rahul.thakur@amiorganics.com</a></p>	<p><b>Registered Office</b> Plot no. 440/4, 5 &amp; 6, Road No. 82/A, GIDC Sachin, Surat- 394230 CIN: L24100GJ2007PLC051093 ISIN: INE00FF01017 NSE Code: AMIORG BSE CODE: 543349 Website: <a href="http://www.amiorganics.com">www.amiorganics.com</a></p>
---	--